Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Name :
Date: 31-Mar-2022
No. of pages: 132
Inquire Before Buying

Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 2, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alcohol Addiction - Overview
Alcohol Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alcohol Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alcohol Addiction - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Aptinyx Inc
Astellas Pharma Inc
Astraea Therapeutics LLC
Avicanna Inc
AWAKN Life Sciences Corp
BioCorRx Inc
Bioprojet SCR
Ceruvia Lifesciences LLC
Chronos Therapeutics Ltd
Clairvoyant Therapeutics Inc
Clearmind Medicine Inc
Colorado Research Partners LLC
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Cybin Inc
Eli Lilly and Co
Journey Colab Corp
Kinnov Therapeutics
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine MindMed Inc
Montisera Ltd
Naprogenix Inc
Neuroepigenix LLC
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pfizer Inc
Protagenic Therapeutics Inc
Psilera Inc
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sobrera Pharma AB
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Whan In Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Alcohol Addiction - Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
Product Description
Mechanism Of Action
acamprosate calcium SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALA-2000 - Drug Profile
Product Description
Mechanism Of Action
arbaclofen ER - Drug Profile
Product Description
Mechanism Of Action
ASP-8062 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
BICX-101 SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
BICX-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BP-1.3656B - Drug Profile
Product Description
Mechanism Of Action
History of Events
brexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-1212 - Drug Profile
Product Description
Mechanism Of Action
CMND-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CYB-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
D-15 - Drug Profile
Product Description
Mechanism Of Action
DCRALDH-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit Fructokinase for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
History of Events
GET-73 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibudilast - Drug Profile
Product Description
Mechanism Of Action
History of Events
JOUR-001 - Drug Profile
Product Description
Mechanism Of Action
JR-220 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
KNX-100 - Drug Profile
Product Description
Mechanism Of Action
MAP-4343 - Drug Profile
Product Description
Mechanism Of Action
midomafetamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
mifepristone - Drug Profile
Product Description
Mechanism Of Action
History of Events
MQ-221 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nezavist - Drug Profile
Product Description
Mechanism Of Action
History of Events
NYPRG-101 - Drug Profile
Product Description
Mechanism Of Action
NYX-783 - Drug Profile
Product Description
Mechanism Of Action
History of Events
odelepran - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ORP-106 - Drug Profile
Product Description
Mechanism Of Action
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Pharmacotherapy for Alcohol Use Disorder - Drug Profile
Product Description
Mechanism Of Action
History of Events
PSIL-002 - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
PT-00114 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PT-150 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RC-132 - Drug Profile
Product Description
Mechanism Of Action
RTI-1395133 - Drug Profile
Product Description
Mechanism Of Action
SKL-10406 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Alcohol Use Disorder - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile
Product Description
Mechanism Of Action
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WIL-1903 - Drug Profile
Product Description
Mechanism Of Action
zolunicant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alcohol Addiction - Dormant Projects
Alcohol Addiction - Discontinued Products
Alcohol Addiction - Product Development Milestones
Featured News & Press Releases
Mar 17, 2022: Clearmind Medicine announces positive results on CMND-100 trials
Feb 28, 2022: MediciNova announces MN-166 (ibudilast) identified as potential beneficial pharmacotherapy for treatment of degenerative cervical myelopathy in Global Spine Journal
Feb 24, 2022: Adial Pharmaceuticals announces completion of last patient, last visit in its ONWARD phase 3 trial of AD04 for the treatment of patients with alcohol use disorder
Feb 22, 2022: MediciNova announces MN-166 (ibudilast) identified as promising pharmacotherapy for alcohol use disorder in drugs
Jan 28, 2022: Clearmind Medicine partners with Dr. Gabor Mate to discuss alcohol use disorder and trauma in a special virtual Event on February 3
Jan 27, 2022: MediciNova receives a notice of intention to grant for a new patent covering MN-166 (ibudilast) for the treatment of alcohol use disorder in Europe
Jan 20, 2022: Opiant Pharmaceuticals announces first patient dosed in phase 2 trial of OPNT002, nasal Naltrexone, for alcohol use disorder
Jan 20, 2022: Clairvoyant Therapeutics receives approval in Canada to initiate a world-leading psilocybin trial for treatment of alcohol use disorder
Jan 19, 2022: Awakn Life Sciences signs MOU With MAPS
Jan 11, 2022: Awakn announces positive results from phase II A/B clinical trial
Dec 08, 2021: Cybin confirms scientific advice meeting with UK Medical and Healthcare Products Regulatory Agency for lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder
Nov 16, 2021: Awakn Life Sciences signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a view of increasing access to psychedelic-assisted psychotherapy in the UK
Nov 08, 2021: Cybin announces positive CYB003 data demonstrating significant advantages over oral psilocybin for treatment of mental health
Nov 04, 2021: Awakn Life Sciences announces the findings from phase II A/B study are to be published In American Journal Of Psychiatry
Oct 26, 2021: Clearmind signs development and supply agreement to produce its drug candidate MEAI psychedelic molecule with Aragen Life Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Alcohol Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, 2022
Alcohol Addiction - Pipeline by Adial Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Alar Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Aptinyx Inc, 2022
Alcohol Addiction - Pipeline by Astellas Pharma Inc, 2022
Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, 2022
Alcohol Addiction - Pipeline by Avicanna Inc, 2022
Alcohol Addiction - Pipeline by AWAKN Life Sciences Corp, 2022
Alcohol Addiction - Pipeline by BioCorRx Inc, 2022
Alcohol Addiction - Pipeline by Bioprojet SCR, 2022
Alcohol Addiction - Pipeline by Ceruvia Lifesciences LLC, 2022
Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, 2022
Alcohol Addiction - Pipeline by Clairvoyant Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Clearmind Medicine Inc, 2022
Alcohol Addiction - Pipeline by Colorado Research Partners LLC, 2022
Alcohol Addiction - Pipeline by Confluence Pharmaceuticals LLC, 2022
Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Curemark LLC, 2022
Alcohol Addiction - Pipeline by Cybin Inc, 2022
Alcohol Addiction - Pipeline by Eli Lilly and Co, 2022
Alcohol Addiction - Pipeline by Journey Colab Corp, 2022
Alcohol Addiction - Pipeline by Kinnov Therapeutics, 2022
Alcohol Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Alcohol Addiction - Pipeline by Laboratorio Farmaceutico CT Srl, 2022
Alcohol Addiction - Pipeline by Lohocla Research Corp, 2022
Alcohol Addiction - Pipeline by Mapreg SAS, 2022
Alcohol Addiction - Pipeline by Mind Medicine MindMed Inc, 2022
Alcohol Addiction - Pipeline by Montisera Ltd, 2022
Alcohol Addiction - Pipeline by Naprogenix Inc, 2022
Alcohol Addiction - Pipeline by Neuroepigenix LLC, 2022
Alcohol Addiction - Pipeline by Novo Nordisk AS, 2022
Alcohol Addiction - Pipeline by Omeros Corp, 2022
Alcohol Addiction - Pipeline by Opiant Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Orphomed Inc, 2022
Alcohol Addiction - Pipeline by Osmotica Pharmaceutical Corp, 2022
Alcohol Addiction - Pipeline by Palisades Therapeutics, 2022
Alcohol Addiction - Pipeline by Pfizer Inc, 2022
Alcohol Addiction - Pipeline by Protagenic Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Psilera Inc, 2022
Alcohol Addiction - Pipeline by Sage Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Alcohol Addiction - Pipeline by Sobrera Pharma AB, 2022
Alcohol Addiction - Pipeline by South Plains Biotechnology Inc, 2022
Alcohol Addiction - Pipeline by Syntropharma Ltd, 2022
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Alcohol Addiction - Pipeline by VM Discovery Inc, 2022
Alcohol Addiction - Pipeline by Whan In Pharm Co Ltd, 2022
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, 2022
Alcohol Addiction - Dormant Projects, 2022
Alcohol Addiction - Dormant Projects, 2022 (Contd..1)
Alcohol Addiction - Dormant Projects, 2022 (Contd..2)
Alcohol Addiction - Discontinued Products, 2022

List of Figures
Number of Products under Development for Alcohol Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
  • Central Nervous System Disorder Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 116
    This study focuses on China's Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of g......
  • Central Nervous System Disorder Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 48
    This study focuses on China's Central Nervous System Disorder Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market fo......
  • Central Nervous System Disorder Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 214
    China's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, in......
  • Global Drugs of Nervous System Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 14-Nov-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Drugs of Nervous System market: According to our latest research, the global Drugs of Nervous System market looks promising in the next 5 years. As of 2022, the global Drugs of Nervous System market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, ......
  • Central Nervous System Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 650
    Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of central nervous system deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal te......
  • Global Drugs of Nervous System Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 24-Feb-2023        Price: US 3260 Onwards        Pages: 123
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The Drugs of Nervous System market revenue was XX Million USD in 2022, and will r......
  • Global Drugs of Nervous System Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 26-Jan-2023        Price: US 3450 Onwards        Pages: 111
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The report focuses on the Drugs of Nervous System market size, segment si......
  • Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 71
    Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2022, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures......
  • Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 40
    Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Drugs In Development, 2022, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs